IRVINE, CA — Irvine Pharmaceutical Services announced today its 2013 strategic plan for dramatically increased capacity over the course of this fiscal year.
The company’s move to incorporate its Avrio parenteral manufacturing facility into the Irvine brand in January was the first step in what Dr. Assad J. Kazeminy, CEO and founder, described as a three-prong initiative for aggressive yet stable growth: more highly trained technical personnel, state-of-the-art instrumentation and increased capacity for formulation, biopharmaceuticals and raw material testing.
We have been building to this trajectory for the past five years,” Kazeminy said. “We are ‘just in time’ to meet the quickly expanding needs of the biopharmaceutical industry as it adjusts to an improving economy, mounting regulatory restrictions and faster-to-market demands.”
Since the first of the year, Irvine has increased technical staff across most departments and is budgeted to add an additional 40 over the next 12 months.
The plan, as outlined by Kazeminy “is to double our capacity for our filling (both lyophilized and liquid) formulation, and biopharmaceutical development before second quarter 2014. We are committed to our clients and relish the challenge and opportunity.”
Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine proves full cGMP specialized product development services such as preformulation/formulation, analytical development, parenteral manufacturing, stability storage and complete analytical CMC testing. Learn more at www.irvinepharma.com or call 877-445-6554.
Irvine Pharmaceutical Services
Irvine, California 92618
T: (877) 445-6554
F: (949) 951-4909